The Truth Behind the Global Chip Shortage
GM and Toyota factories are shutting down...Mass shortages of electronics...Medical device production nearly halted...

And what happens next for investors.
Click Here to See His Urgent Warning.
Burke W. Whitman, insider at Amicus Therapeutics
Burke W. Whitman Insider Alerts

Get notified the next time Burke W. Whitman buys or sells Amicus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Burke W. Whitman Insider Information

Director of Amicus Therapeutics
Mr. Whitman has served as a member of the Board since 2019.  He leads and governs mission-driven organizations in business, national service, and civil society.  Since 2019 he serves as CEO, Colmar Holdings (private); Board of Directors, Amicus Therapeutics; Board of Directors, Omega Healthcare Investors; Board of Advisors, Secretary of Defense (Reserve Forces Policy Board); and Board of Trustees, The Lovett School.  Formerly in business 1988-2008, he served as CEO, HMA (Fortune 500, sold); CFO, Triad Hospitals (Fortune 500, sold); President, Deerfield Healthcare (private, sold); VP, Almost Family; and Investment Banker, Morgan Stanley.  Concurrently in national service 1985-2018, he served as a reserve officer of the U.S. Marine Corps including active duty 1985-1988 and 2009-2018, led five combat deployments, was Commanding General of 4th Marine Division and Marine Forces Reserve, served with the Secretary of Defense, and completed uniformed service as a Major General and the Corps’ senior reservist.  For civil society, he has served on the Boards of the Federation of American Hospitals, Toys for Tots Foundation, Marine Corps University, and on the Founders Group of the National Museum of the Marine Corps.  He is a graduate of Harvard Business School, Army War College, and Dartmouth College.

Mr. Whitman serves as member of the Nominating and Governance Committee and as member of the Audit and Compliance Committee.

What is Burke W. Whitman's net worth?

The estimated net worth of Burke W. Whitman is at least $230,563.14 as of September 1st, 2021. Mr. Whitman owns 25,034 shares of Amicus Therapeutics stock worth more than $230,563 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Whitman may own. Learn More.

How do I contact Burke W. Whitman?

The corporate mailing address for Mr. Whitman and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]

Has Burke W. Whitman been buying or selling shares of Amicus Therapeutics?

Burke W. Whitman has not been actively trading shares of Amicus Therapeutics during the last ninety days. Most recently, on Monday, November 1st, Burke W. Whitman bought 1,500 shares of Amicus Therapeutics stock. The stock was acquired at an average cost of $10.49 per share, with a total value of $15,735.00.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director).

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 8 times. They purchased a total of 39,105 shares worth more than $354,377.70. During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 569,658 shares worth more than $6,693,258.28. The most recent insider tranaction occured on January, 18th when CEO John F Crowley sold 8,564 shares worth more than $87,609.72. Insiders at Amicus Therapeutics own 2.5 % of the company.

Information on this page was last updated on 1/18/2022.

Burke W. Whitman Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2021Buy1,500$10.49$15,735.00View SEC Filing Icon  
10/1/2021Buy1,500$9.56$14,340.00View SEC Filing Icon  
9/1/2021Buy1,500$11.41$17,115.00View SEC Filing Icon  
7/1/2021Buy1,500$9.60$14,400.0059,082View SEC Filing Icon  
6/1/2021Buy1,500$9.24$13,860.0047,467View SEC Filing Icon  
4/1/2021Buy1,500$10.00$15,000.0044,467View SEC Filing Icon  
1/4/2021Buy1,500$23.17$34,755.0039,967View SEC Filing Icon  
12/1/2020Buy1,500$23.50$35,250.0038,467View SEC Filing Icon  
11/2/2020Buy1,500$18.01$27,015.0036,967View SEC Filing Icon  
10/1/2020Buy1,500$14.28$21,420.0035,467View SEC Filing Icon  
9/1/2020Buy1,500$14.62$21,930.0033,967View SEC Filing Icon  
7/1/2020Buy1,500$15.20$22,800.0030,967View SEC Filing Icon  
8/23/2019Buy4,945$10.07$49,796.1521,612View SEC Filing Icon  
See Full Table

Burke W. Whitman Buying and Selling Activity at Amicus Therapeutics

This chart shows Burke W Whitman's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $9.21
Low: $9.18
High: $9.91

50 Day Range

MA: $11.04
Low: $9.21
High: $12.48

2 Week Range

Now: $9.21
Low: $8.40
High: $21.34


2,238,868 shs

Average Volume

4,022,053 shs

Market Capitalization

$2.57 billion

P/E Ratio


Dividend Yield



Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!